Jake Simson, PhD

Partner

Jake Simson is a Partner at RA Capital Management. Jake’s primary responsibilities are to work on both public and private investments and serve as a Board Director for Bicara Therapeutics, Janux Therapeutics, Parabilis Medicines, Septerna, Tyra Biosciences, Convergent Therapeutics, Outpace Bio, and Vivace Therapeutics. Prior to RA Capital, Jake covered solid tumor oncology landscapes. In his doctoral research, Jake investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. Jake holds a BS in Materials Science and Engineering from the Massachusetts Institute of Technology and a PhD in Biomedical Engineering from Johns Hopkins University.